IMB Dx, Inc. provides liquid biopsy platform in South Korea. It offers AlphaLiquid Platform that provides circulation-tumor DNA-based precision diagnostics solutions across various stages of cancer for patients, survivors, and individuals; and AlphaLiquid 100 test, a tool that enables the detection of biomarkers across 118 cancer-related genes through one blood test. The company also provides CancerDetect, a liquid biopsy platform for the early detection of cancer recurrence post-surgery; and CancerFind, a blood-based test for various cancer early detection. IMB Dx, Inc. was founded in 2018 and is based in Seoul, South Korea.
Metrics to compare | 461030 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship461030PeersSector | |
|---|---|---|---|---|
P/E Ratio | Unlock | NaN | NaN | Unlock |
PEG Ratio | Unlock | NaN | NaN | Unlock |
Price/Book | Unlock | NaN | NaN | Unlock |
Price / LTM Sales | Unlock | NaN | NaN | Unlock |
Upside (Analyst Target) | Unlock | NaN | NaN | Unlock |
Fair Value Upside | Unlock | NaN | NaN | Unlock |